BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33475835)

  • 1. Pleural mesothelioma classification update.
    Beasley MB; Galateau-Salle F; Dacic S
    Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleural mesothelioma classification-update and challenges.
    Dacic S
    Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
    Hakim SA; Abou Gabal HH
    Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
    [No Abstract]   [Full Text] [Related]  

  • 6. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
    Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
    Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
    Bruno R; Alì G; Poma AM; Proietti A; Libener R; Mariani N; Niccoli C; Chella A; Ribechini A; Grosso F; Fontanini G
    J Mol Diagn; 2020 Apr; 22(4):457-466. PubMed ID: 32036091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years.
    Hidaka K; Takeda T; Kinoshita Y; Nabeshima K; Tamiya S; Yoshikawa Y; Tsujimura T
    Pathol Int; 2020 Dec; 70(12):1009-1014. PubMed ID: 32956524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.
    Amacher V; Bode PK; Moch H; Lenggenhager D; Vrugt B
    Acta Cytol; 2023; 67(4):444-450. PubMed ID: 36889303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
    Zaleski M; Kalhor N; Fujimoto J; Wistuba I; Moran CA
    Pathol Res Pract; 2020 Dec; 216(12):153267. PubMed ID: 33176261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
    Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
    Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic mesothelioma biomarkers in effusion cytology.
    Eccher A; Girolami I; Lucenteforte E; Troncone G; Scarpa A; Pantanowitz L
    Cancer Cytopathol; 2021 Jul; 129(7):506-516. PubMed ID: 33465294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G; Özekinci S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.